Abbisko Cayman Limited (HKG:2256)
Hong Kong · Delayed Price · Currency is HKD 8.52
+0.17 (1.97%)
Sep 11, 2026, 4:08 PM HKT
Abbisko Cayman Revenue
Abbisko Cayman had revenue of 97.27M CNY in the half year ending June 30, 2026, a decrease of -80.44%. This brings the company's revenue in the last twelve months to 97.27M, down -84.28% year-over-year. In the year 2025, Abbisko Cayman had annual revenue of 612.12M with 21.45% growth.
Revenue (ttm)
97.27M CNY
Revenue Growth
-84.28%
P/S Ratio
49.38
Revenue / Employee
340.09K CNY
Employees
286
Market Cap
5.55B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 612.12M | 108.13M | 21.45% |
| Dec 31, 2024 | 503.99M | 484.93M | 2,544.24% |
| Dec 31, 2023 | 19.06M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 22.68M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.52B |
| Shanghai Haohai Biological Technology | 2.68B |
| Lepu Biopharma | 1.14B |
| Ocumension Therapeutics | 1.08B |
| Jacobio Pharmaceuticals Group | 852.85M |
| Alphamab Oncology | 598.06M |
| CARsgen Therapeutics Holdings | 157.72M |
| Shanghai Bao Pharmaceuticals | 19.67M |
Abbisko Cayman News
- 2 months ago - Abbisko Therapeutics And AstraZeneca Enter Strategic Collaboration For Lumipodlin - Nasdaq
- 2 months ago - Abbisko Therapeutics Collaborates With Eli Lilly For Research And Development; Stock Up - Nasdaq
- 2 months ago - Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly - Reuters